Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05697406 · ClinicalTrials.gov registry record · Phase 1
HP Pyruvate MRI in Cancers
A Phase 1 study of Tumors and Image, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05697406: Recruiting Phase 1 study of Tumors and Image, sponsored by University of Maryland, Baltimore.
NCT05697406 is a Phase 1 study of Tumors and Image that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 25 participants, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05697406, a Phase 1 study of Tumors and Image, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.
Primary Outcome
Imaging Quality, KpL
Conditions Studied
Interventions
- DRUG Hyperpolarized 13C-Pyruvate
Study Locations (1)
Maryland
- University of Maryland Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
What NCT05697406 shows while recruiting
NCT05697406 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 198-participant average among 20 other Tumors trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized 13C-Pyruvate is the first listed.
NCT05697406 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05697406 about?
NCT05697406 is a clinical study titled "HP Pyruvate MRI in Cancers". Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruv...
What is the current status of trial NCT05697406?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2024-06-24. Estimated completion is 2028-12-01.
What conditions does trial NCT05697406 study?
This clinical trial studies the following conditions: Tumors, Image, Warburg Effect.
What interventions are being tested in trial NCT05697406?
The interventions under investigation include: Hyperpolarized 13C-Pyruvate (DRUG).
Who is sponsoring clinical trial NCT05697406?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05697406 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05697406's enrollment target sits among peer trials
25 17th of 20 higher than 3 of 20 other Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Advanced Solid Tumor Malignancies
COMPLETED · Phase 1
-
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
COMPLETED · Phase 1
-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
COMPLETED · Phase 1
-
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI